Literature DB >> 16250259

Influence of famotidine on verapamil pharmacokinetics in rats.

Kamal M Matar1.   

Abstract

The effect of famotidine (4 mg/kg, p.o.) on the kinetic profile of co-administered verapamil (20 mg/kg(-1), p.o.) was studied in the rat. Plasma verapamil levels were collected serially for 12 h and measured using sensitive HPLC method. The pharmacokinetic parameters (elimination half-life, area under the plasma concentration-time curve, peak plasma levels and the times to attain these plasma levels) of verapamil were evaluated in the rat. The results indicate that co-administered famotidine did not significantly alter the pharmacokinetic profile of verapamil in the rat. The present finding suggests that famotidine may safely be co-administered with verapamil but clearly further studies in human subjects are needed to reliably rule out the potential interaction of these two drugs.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16250259     DOI: 10.1007/BF03190622

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.441


  30 in total

Review 1.  Recent advances in pharmaceutical chemistry--review II. Histamine H2-receptor antagonists.

Authors:  R M Lee; R D McDowall
Journal:  J Clin Hosp Pharm       Date:  1986-12

Review 2.  Review article: drug interactions with agents used to treat acid-related diseases.

Authors:  T J Humphries; G J Merritt
Journal:  Aliment Pharmacol Ther       Date:  1999-08       Impact factor: 8.171

3.  The effects of cimetidine, ranitidine and famotidine on rat hepatic microsomal cytochrome P-450 activities.

Authors:  A Bast; K Smid; H Timmerman
Journal:  Agents Actions       Date:  1989-04

4.  Physiological disposition of verapamil in man.

Authors:  M Schomerus; B Spiegelhalder; B Stieren; M Eichelbaum
Journal:  Cardiovasc Res       Date:  1976-09       Impact factor: 10.787

5.  Pharmacokinetics of cefpodoxime proxetil and interactions with an antacid and an H2 receptor antagonist.

Authors:  N Saathoff; H Lode; K Neider; K M Depperman; K Borner; P Koeppe
Journal:  Antimicrob Agents Chemother       Date:  1992-04       Impact factor: 5.191

6.  The pharmacology of verapamil. IV. Kinetic and dynamic effects after single intravenous and oral doses.

Authors:  R G McAllister; E B Kirsten
Journal:  Clin Pharmacol Ther       Date:  1982-04       Impact factor: 6.875

7.  Physiological pharmacokinetics and pharmacodynamics of (+/-)-verapamil in female rats.

Authors:  E L Todd; D R Abernethy
Journal:  Biopharm Drug Dispos       Date:  1987 May-Jun       Impact factor: 1.627

Review 8.  Pharmacology of gastric acid inhibition.

Authors:  R D Shamburek; M L Schubert
Journal:  Baillieres Clin Gastroenterol       Date:  1993-03

Review 9.  Clinical pharmacokinetics of verapamil, nifedipine and diltiazem.

Authors:  H Echizen; M Eichelbaum
Journal:  Clin Pharmacokinet       Date:  1986 Nov-Dec       Impact factor: 6.447

10.  Intravenous verapamil kinetics in rats: marked arteriovenous concentration difference and comparison with humans.

Authors:  P Manitpisitkul; W L Chiou
Journal:  Biopharm Drug Dispos       Date:  1993-10       Impact factor: 1.627

View more
  1 in total

1.  Effect of experimentally induced hepatic and renal failure on the pharmacokinetics of topiramate in rats.

Authors:  Kamal M Matar; Yasin I Tayem
Journal:  Biomed Res Int       Date:  2014-06-09       Impact factor: 3.411

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.